All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 4 read as filed from the record and 5 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2024-01-25.
From the record
Zentalis Pharmaceuticals, Inc.'s filings since 2017 show 2 warning events: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2024-01-25) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
4 filed years; profitable in 0 of 4.
From the record
Zentalis Pharmaceuticals, Inc.'s 4 filed years say what it did: it rose in 0 of 1 years; the deepest fall was 100% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Zentalis Pharmaceuticals, Inc.'s shareholder treatment is put at 6.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 37% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -63%: lost 63¢ per shareholder dollar. Leverage 25%: owes 25¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Zentalis Pharmaceuticals, Inc. lost about 63 cents for every dollar of shareholders' money. Leverage: it owed about 25 cents per dollar of assets, and net share issuance: its share count grew 1.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
SI estimate 5.2/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Zentalis Pharmaceuticals, Inc.'s industry position is put at 5.2 of 10 with a confidence of 20 of 100, because no filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 315 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are the people in charge doing?
bottom 19% of 315 in its family for leadership; chief executive since 2024.
From the record
Zentalis Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Eastland, Julia Marie (CEO & President, as filed), filing under that title since 2024-11-13, 2 years (bottom 23% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 2.5 years (bottom 11%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 24%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
SI estimate 3.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Zentalis Pharmaceuticals, Inc.'s room to expand is put at 3.1 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the bottom 31% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
SI estimate 2.4/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Zentalis Pharmaceuticals, Inc.'s growth drivers is put at 2.4 of 10 with a confidence of 35 of 100, because read from one part only, the three-year growth of research spending, which ranks in the bottom 24% of 323 in its family; the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending. A filing that carries the missing parts replaces this estimate with the filed reading.
Did its newest year beat what its own record pointed to?
SI estimate 6.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Zentalis Pharmaceuticals, Inc.'s expectations vs reality is put at 6.3 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the top 37% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made